Non-Irradiated Tissue Sterilization: 30 Years of Preserving Biological Integrity

PuroGen's involvement in allograft tissue sterilization began in 1996 — when VHP sterilization was not yet an established sterilization category, ISO 22441 did not exist, and the industry's working assumption was that gamma irradiation was the only viable path to terminal sterilization for cadaveric tissue.

That assumption was wrong. The clinical value of allograft tissue is embedded in its biology — in the collagen integrity that gives cortical bone its structural performance, in the bone morphogenetic proteins that give demineralized bone matrix its osteoinductive capacity, in the tensile architecture that gives tendon its mechanical function. Any sterilization method that destroys what makes the graft work has not solved the problem. It has displaced it.

PuroGen's founding commitment was to sterilize tissue without sterilizing its biology. Twenty-eight years of validation work across five allograft tissue categories constitute the evidence base for that commitment.

The Irradiation Problem: Why the Default Method Is Not the Right One

Gamma irradiation has been the default terminal sterilization method for allograft tissue for decades. It is logistically accessible — a network of commercial irradiation facilities provides contract services to tissue banks across the country. It is technically effective at microbial inactivation. And it is deeply embedded in existing tissue bank operations and regulatory submissions.

It is also, by mechanism, destructive to the biological structures that define allograft clinical value.

Gamma photons interact with tissue through two pathways. Direct effects include strand breaks in microbial DNA — the intended sterilization mechanism. Indirect effects arise from the radiolysis of water molecules within the tissue, generating hydroxyl free radicals (•OH) and other reactive oxygen species. These free radicals are not selective. They react with any organic molecule in their vicinity — microbial DNA, but also collagen chains, structural proteins, and the growth factors embedded in the extracellular matrix.

A 2024 study published in Cell & Tissue Banking documented dose-dependent collagen fragmentation in cortical bone at standard gamma sterilization doses of 25 kGy. Biomechanical consequences include reductions in fatigue crack propagation resistance of up to 15-fold — the property that determines whether a structural allograft can withstand the cyclic loading environment it was selected for. A 2025 study in BMC Musculoskeletal Disorders documented 20–30% reductions in ultimate load capacity in tendon allografts at standard irradiation doses. A 2022 study in the Journal of Functional Biomaterials confirmed dose-dependent reduction in the osteoinductive properties of demineralized bone matrix — the precise property that demineralization processing was designed to produce.

The damage is dose-dependent and present at all sterilization-relevant doses. There is no irradiation dose that achieves SAL 10⁻⁶ without initiating free radical-mediated degradation of the tissue's biological components. Protective protocols during irradiation — dry ice cooling, cryogenic conditions — attenuate the damage. They do not eliminate it.

For a tissue bank whose product's clinical value is its biology, this is not a processing artifact to be noted in fine print. It is the central constraint that the sterilization choice must resolve.

The VHP Mechanism: Why the Damage Does Not Occur

Vaporized hydrogen peroxide sterilization operates through gas-phase oxidative inactivation of microorganisms at controlled temperatures between 25°C and 50°C. There is no ionizing radiation. There are no gamma photons, no radiolysis, no hydroxyl free radical generation from ionizing energy transfer.

VHP's microbicidal mechanism is direct oxidative inactivation — hydrogen peroxide vapor interacts with microbial cell membranes and enzymatic systems. This mechanism is lethal to microorganisms and achieves SAL 10⁻⁶. At the temperatures where VHP operates (25–50°C), collagen denaturation does not occur — onset of thermal collagen denaturation requires temperatures above 60°C for most allograft tissue types. Growth factor proteins retain their tertiary structure and biological activity. The collagen scaffold architecture that supports bone ingrowth and tissue integration remains intact.

After the sterilization cycle, hydrogen peroxide vapor decomposes completely to water and oxygen. No residue remains on the tissue. No aeration period is required. The graft that enters the sterilization cycle in a biologically intact state exits in a biologically intact state — sterile.

A 2026 study in Pharmaceutical Research examining VHP sterilization of polymer scaffolds confirmed preservation of molecular weight and chemical integrity across all tested materials, with FTIR analysis confirming no chemical changes attributable to the process. While this study addressed implantable polymers rather than allograft tissue directly, the principle — that VHP sterilization does not induce the oxidative degradation characteristic of ionizing radiation — applies to tissue applications where collagen and growth factor preservation are the critical biological parameters.

Validated Across Five Tissue Categories

PuroGen has validated VHP sterilization processes for allograft tissue across cortical bone, cancellous bone, tendon, dermis, and amniotic membrane. Each tissue type presents a distinct sterilization challenge that requires its own validated parameter set.

**Cortical bone** is the densest allograft category — high mineral content, low porosity, substantial structural load-bearing function. Sterilization parameters must achieve adequate VHP penetration through compact bone matrix while operating at temperatures that preserve collagen mechanical properties. The validation evidence base for cortical bone includes post-sterilization biomechanical testing confirming retention of fatigue crack propagation resistance and compressive strength.

**Cancellous bone** presents a different profile — high porosity, lower density, primary function as an osteoconductive scaffold for bone ingrowth. The trabecular architecture that makes cancellous bone osteoconductive also creates accessible surface area for VHP contact, making sterilization efficacy more straightforward to achieve. The validation focus is on confirming preservation of the collagen framework that the trabecular scaffold depends on.

**Tendon** is the tissue category where mechanical property preservation is most clinically critical — and where the published evidence on irradiation damage is most directly relevant to patient outcomes. VHP sterilization of tendon allografts is validated against mechanical testing endpoints: ultimate load capacity, stiffness, and energy absorption. The validated process parameters maintain these properties within ranges established from fresh-frozen reference tissue.

**Dermis** presents distinct considerations: lower structural mechanical requirements than bone or tendon, but significant moisture content and sensitivity to temperature and humidity conditions that affect collagen architecture. Validated parameters for dermal allografts are developed around the specific biological characteristics of skin-derived collagen.

**Amniotic membrane** is the most biologically sensitive category in the portfolio — growth factor content, membrane integrity, and cellular bioactivity are all relevant to its clinical applications. The validated process parameters for amniotic membrane operate at the lower end of the VHP temperature range to preserve the biological activity of growth factors and cytokines that distinguish membrane-derived grafts from simpler scaffold materials.

No two tissue types are sterilized under identical parameters. PuroGen's SteriFlex platform's programmable parametric control — independent specification of VHP concentration, temperature, humidity, exposure time, and aeration for each product — is not a convenience feature. It is the technical requirement that makes multi-tissue-type VHP validation achievable on a single platform.

The Regulatory and Standards Framework

VHP sterilization was reclassified to FDA Established Category A in January 2024, placing it alongside steam, EtO, dry heat, and radiation as a recognized sterilization method with an established evidence base. ISO 22441:2022 provides the international standard for VHP process development, validation, and routine control.

For tissue banks operating under FDA CGTP (21 CFR Part 1271) and AATB Standards, the relevant framework is different from 510(k)/PMA device submissions — but the validation structure is analogous. AATB Standards E2.800 series governs sterilization validation for tissue establishments: process development, performance qualification, biological indicator program, and ongoing monitoring. ISO 22441 provides the technical methodology within which that validation is executed. FDA CGTP requires tissue banks to maintain procedures for all HCT/P manufacturing steps, including terminal sterilization, with documented evidence of process control.

A tissue bank validating VHP sterilization per ISO 22441, within the quality framework required by AATB and CGTP, is using a recognized, auditable methodology — one that AATB auditors and FDA inspectors can evaluate against published standards. This is what "established method" means in practice: the regulatory and accreditation frameworks have a defined structure for assessing it.

The Deeper Series

This article provides the institutional and technical foundation for understanding non-irradiated tissue sterilization. PuroGen's Insights series includes detailed treatments of specific dimensions of this topic:

The biological damage mechanisms of gamma irradiation — the specific published evidence on collagen fragmentation, growth factor denaturation, and mechanical property loss — are examined in depth in [Why Irradiation Sterilizes the Biology Out of Your Allograft](/insights/irradiation-allograft-biological-damage).

The operational and regulatory case for tissue banks bringing sterilization in-house — the custody break, the AATB and CGTP accountability structure, and the competitive positioning argument — is developed in [Complete Custody and Control: Why Tissue Banks Are Bringing Sterilization In-House](/insights/tissue-bank-sterilization-custody-control).

The clinical argument for non-irradiated allografts — osteoinductivity, osteoconductivity, and mechanical integrity as clinically measurable properties that sterilization method choice determines — is addressed in [The Clinical Case for Non-Irradiated Allografts](/insights/non-irradiated-allograft-clinical-advantages).

Frequently Asked Questions

**When did PuroGen begin validating VHP sterilization for allograft tissue?**

PuroGen's tissue sterilization work began in 1996 with cadaveric allograft tissue — nearly three decades before FDA's January 2024 Category A reclassification of VHP. That validation heritage spans cortical bone, cancellous bone, tendon, dermis, and amniotic membrane. Each tissue type has been validated against its specific biological and structural requirements under the IQ/OQ/PQ framework, with biological indicator challenges and post-sterilization biomechanical and biological activity testing. The evidence base accumulated over those years is one of the most extensive records of non-irradiated tissue sterilization in the industry.

**Does VHP sterilization achieve SAL 10⁻⁶ for allograft tissue?**

Yes. VHP sterilization achieves SAL 10⁻⁶ — a one-in-a-million probability of a non-sterile unit — through gas-phase oxidative inactivation, validated using *Geobacillus stearothermophilus* biological indicators under the half-cycle method specified in ISO 22441:2022. The sterility assurance level is equivalent to gamma irradiation. What differs is the mechanism — and the biological consequences of that mechanism on the tissue's collagen, growth factors, and mechanical properties.

**What AATB and FDA regulatory frameworks govern VHP tissue sterilization?**

Tissue banks validating VHP sterilization operate under FDA CGTP (21 CFR Part 1271), which requires tissue establishments to establish and maintain procedures for all HCT/P manufacturing steps, including terminal sterilization. AATB Standards E2.800 series governs sterilization validation for accredited tissue establishments. ISO 22441:2022 provides the recognized technical methodology for VHP process development and validation. These frameworks are compatible — ISO 22441-aligned validation documentation integrates into AATB- and CGTP-compliant quality systems without requiring a new quality infrastructure.

**Why does VHP require programmable parametric control for tissue applications?**

Different allograft tissue types have different density, porosity, moisture content, and biological sensitivity profiles that require different validated sterilization parameters. A cortical bone allograft requires different VHP concentration, temperature, and humidity conditions than an amniotic membrane graft. A tendon allograft requires different exposure conditions than cancellous bone. A fixed-parameter sterilization system optimized for one tissue type will either under-sterilize or over-expose other types. Programmable parametric control — independent specification of VHP concentration, temperature, humidity, exposure time, and aeration — is the technical requirement for a single platform that can validate and run multiple tissue types correctly.

**Can tissue banks access VHP sterilization without building the full infrastructure from scratch?**

Yes. PuroGen's commercial models — direct system deployment of the SteriFlex platform, private label manufacturing where PuroGen provides sterilization services under the tissue bank's brand, and strategic collaboration for organizations seeking deeper integration — provide pathways for tissue banks at different stages of development and with different capital and regulatory strategies. The SteriFlex platform is modular and can be commissioned within existing tissue processing facility spaces, without the radiation shielding, NRC licensing, or dedicated irradiation infrastructure that gamma irradiation requires.